GMS PM 843 Pharmacologic Intervention in Inflammatory Responses
Tuesdays, 10:00 – 11:50 am, January 19 – May 1
Topics:
Introduction to Inflammation:Susan Leeman, PhD (BU), Karen Reed, PhD (BU)
Inflammation and Obesity:Salomon Amar, DMD, PhD (BU)
Inflammation and HIV Infection:Steven Douglas, MD, (University of Pennsylvania)
Inflammation and Cancer:Hava Avraham, PhD (Harvard)
Inflammation and Pulmonary Disease:Cara Williams, PhD and Deborah A. Young, PhD (Wyeth Pharmaceuticals)
Inflammation and Neurodegenerative Diseases:Ben Wolozin, MD, PhD and Carmela Abraham, PhD (BU)
Inflammation and the GI Tract:Joel Weinstock, MD (Tufts Medical Center)
Inflammation and Postoperative Adhesion Formation:Karen Reed, PhD (BU)
Inflammation and Adenosine Receptors: Katya Ravid, PhD (BU)
Resolution of Inflammation
ASSIGNMENTS:
Student evaluations will be based on presentations of review and research articles (50%), participation in class discussion (25%), and a short research paper on a novel idea for pharmacologic intervention of an inflammatory process (25%).
Susan E. Leeman, Ph.D., R-616, 8-4364, sleeman@bu.edu
Professor of Pharmacology Dr. Leeman’s work focuses on the two peptides, substance P (SP) and neurotensin, which were isolated and chemically defined in her laboratory. Projects that are currently underway include: 1. the role of glycosylation of the NK1 receptor on its signal transduction pathways, 2. the roles of SP in several models of inflammation in the gastrointestinal tract, including post-surgical cell adhesion formation, and the effect of non-peptide SP antagonists. 3. the role of LITAF, a newly described transcription factor participating in TNF alpha synthesis in macrophages obtained from inflamed colonic tissue.
Karen Reed, Ph.D., W-402, 8-5704, klreed@bu.edu
Associate Research Professor of Surgery and Associate Professor of Pharmacology.
Dr. Reed’s research focuses on two areas medically and economically relevant to gastroenterology. One area involves the molecular and cellular characterization of proinflammatory regulators of intra-abdominal adhesion formation while the second area focuses on the etiology of inflammatory bowel disease (IBD). In the area of adhesion formation we have demonstrated that a specific substance P receptor antagonist reduces post-surgical adhesion formation and that this response involves tissue plasminogen activator (tPA), matrix metalloproteinases and oxidative stress. In similar studies we have also shown that HMG-CoA reductase inhibitors reduce adhesion formation. These studies have led to several publications and awards including a paper in the Proceedings of the National Academy of Sciences and a “Best Poster Presentation” award at the international meeting of the Peritoneal Access Society held in Belgium. I am also extremely interested in understanding the pathogenesis of IBD. I have been involved in research to characterize the involvement of the transcription factor NFkB, as well as its upstream activators and downstream mediators, in intestinal inflammation in the rat. I have also contributed to research investigating the role of substance P as well as the transcriptional regulator, LITAF, in intestinal inflammationSyllabus with Lecture Topics:
January 19, 2010: Introduction, class format, logistics, review of syllabus.
Introduction to Inflammation: Drs. Susan Leeman, PhD and Karen Reed, PhD.
January 26, 2010: Cardiovascular Inflammation and Oxidants: Dr. Richard Cohen, MD Department of Medicine, Boston University
Review Article:
Research Paper I:
Research Paper II:
February 2, 2010: Neurokinin-1 Receptor and Substance P – Role in HIV Immunopathogenesis and Therapeutic Intervention: Steven Douglas, MD, University of Pennsylvania
Review Article: Tuluc F, Lai JP, Kilpatrick LE, Evans DL and Douglas SD. Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol. 2009; 6:271-6.
Research Paper I: Lai JP, Ho WZ, Kilpatrick LE, Wang X, Tuluc F, Korchak HM and Douglas SD. Full-Length and Truncated Neurokinin-1 Receptor (NK-1R) Expression and Function during Monocyte-Macrophage Differentiation. Proc. Nat. Acad. Sci. U. S. A. 2006; 103:7771-7776.
Research Paper II: Lai JP, Lai S, Tuluc F, Tansky MF, Kilpatrick LE, Leeman SE and Douglas SD. Differences in the Length of the C-terminus Mediates Functional Properties of Neurokinin-1 Receptor. 2008; Proc. Nat. Acad. Sci. U. S. A. 105:12605-12610.
February 9, 2010: Inflammation and Breast Cancer: Molecular Mechanisms of Inflammatory Breast Carcinoma: Hava Avraham, PhD, Beth Israel Deaconess Medical Center Harvard Medical School
Review Article I: Hojilla CV, Wood GA, Khokha R. Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res. 2008; 10(2):205.
Review Article II: Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F. Defining the molecular biology of inflammatory breast cancer. Semin Oncol. 2008; 35(1):41-50.
Review Article III: Cole SW. Chronic inflammation and breast cancer recurrence. J Clin Oncol. 2009; 27(21):3418-9.
Research Paper I: Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation- induced cell migration and invasion. Cancer Cell. 2009; 15(5):416- 28.
February 23, 2010: Inflammation and Pulmonary Disease: Cara Williams, Ph.D., Wyeth Pharmaceuticals
Review Article:
Research Paper-I:
Research Paper-II:
March 2, 2010: Inflammation and Neurodegenerative Diseases: Dr. Benjamin Wolozin, MD, PhD, Department of Pharmacology and Experimental Therapeutics, Boston University
Review Article I: Heneka MT and O’Banion MK. Inflammatory processes in Alzheimer’s disease. J Neuroimmunol. 2007; 187:69-91.
Review Article II: Perry VH, Cuningham C and Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007; 161 (7):161-167.
Research Paper I: Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E and Nicoll JAR. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008; 371:1-8.
March 16, 2010: Inflammation and Mast Cells: Dr. Theoharis C. Theoharides, MD, PhD, Department of Pharmacology and Experimental Therapeutics, Tufts-New England Medical Center
Review Article:
Research Paper I:
Research Paper II:
March 23, 2010: Inflammation and Neurodegenerative Diseases: Dr. Carmela Abraham, PhD, Department of Biochemistry, Boston University
Review Article:
Research Paper I:
Research Paper II:
March 30, 2010: IL-17 and Intestinal Inflammation: Vijay K. Kuchroo, DVM, PhD., Harvard Medical School
Review Article:
Research Paper I:
Research Paper II:
April 6, 2010: Pharmacologic Inhibition of Adhesion Formation: The Use of Neurokinin-1 Receptor Antagonists and Statins: Karen L Reed, PhD, Boston University
Review Article I: Duron JJ, Postoperative intraperitoneal adhesion pathophysiology. Colorectal Dis. 2007; 9(Suppl. 2):14-24.
Review Article I: Imudia AN, Kumar S, Saed GM and Diamond MP. Pathogenesis of intra-abdominal and pelvic adhesion development. Sem Reprod Med. 2008; 26(4):289-297.
Research Paper I: Kosaka H, Yoshimoto T, Yoshimoto T, Fujimoto J and Nakanishi K. Interferon-γ is a therapeutic target molecule for prevention of postoperative adhesion formation. Nat Med. 2008; 14(4):437-441.
